HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.

Abstract
JAK2V617F(+) myeloproliferative neoplasms (MPNs) frequently progress into leukemias, but the factors driving this process are not understood. Here, we find excess Hedgehog (HH) ligand secretion and loss of PTCH2 in myeloproliferative disease, which drives canonical and noncanonical HH-signaling. Interestingly, Ptch2(-/-) mice mimic dual pathway activation and develop a MPN-phenotype with leukocytosis (neutrophils and monocytes), strong progenitor and LKS mobilization, splenomegaly, anemia, and loss of lymphoid lineages. HSCs exhibit increased cell cycling with improved stress hematopoiesis after 5-FU treatment, and this results in HSC exhaustion over time. Cytopenias, LKS loss, and mobilization are all caused by loss of Ptch2 in the niche, whereas hematopoietic loss of Ptch2 drives leukocytosis and promotes LKS maintenance and replating capacity in vitro. Ptch2(-/-) niche cells show hyperactive noncanonical HH signaling, resulting in reduced production of essential HSC regulators (Scf, Cxcl12, and Jag1) and depletion of osteoblasts. Interestingly, Ptch2 loss in either the niche or in hematopoietic cells dramatically accelerated human JAK2V617F-driven pathogenesis, causing transformation of nonlethal chronic MPNs into aggressive lethal leukemias with >30% blasts in the peripheral blood. Our findings suggest HH ligand inhibitors as possible drug candidates that act on hematopoiesis and the niche to prevent transformation of MPNs into leukemias.
AuthorsClaudius Klein, Anabel Zwick, Sandra Kissel, Christine Ulrike Forster, Dietmar Pfeifer, Marie Follo, Anna Lena Illert, Sarah Decker, Thomas Benkler, Heike Pahl, Robert A J Oostendorp, Konrad Aumann, Justus Duyster, Christine Dierks
JournalThe Journal of experimental medicine (J Exp Med) Vol. 213 Issue 2 Pg. 273-90 (Feb 08 2016) ISSN: 1540-9538 [Electronic] United States
PMID26834157 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2016 Klein et al.
Chemical References
  • Hedgehog Proteins
  • Ligands
  • Mutant Proteins
  • PTCH2 protein, human
  • Patched Receptors
  • Patched-2 Receptor
  • Ptch2 protein, mouse
  • Receptors, Cell Surface
  • Recombinant Proteins
  • JAK2 protein, human
  • Janus Kinase 2
Topics
  • Animals
  • Disease Progression
  • Hedgehog Proteins (metabolism)
  • Hematopoiesis
  • Hematopoietic Stem Cells (metabolism, pathology)
  • Humans
  • Janus Kinase 2 (genetics, metabolism)
  • Leukemia (etiology, genetics, metabolism)
  • Ligands
  • Lymphopenia (etiology)
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Mutant Proteins (genetics, metabolism)
  • Myeloproliferative Disorders (etiology, genetics, metabolism)
  • Osteoblasts (metabolism, pathology)
  • Patched Receptors
  • Patched-2 Receptor
  • Phenotype
  • Polycythemia Vera (genetics, metabolism, pathology)
  • Receptors, Cell Surface (deficiency, genetics)
  • Recombinant Proteins (genetics, metabolism)
  • Signal Transduction
  • Stem Cell Niche

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: